- Investing Ideas
- /
- U.S. Pharmaceuticals & Biotech Solid Balance Sheet and Fundamentals
U.S. Pharmaceuticals & Biotech Solid Balance Sheet and Fundamentals
Results
16
High return on equity, past performance and sound balance sheet.
16 companies
Medpace Holdings
Market Cap: US$15.3b
Provides clinical research-based drug and medical device development services in North America, Europe, and Asia.
MEDP
US$546.74
7D
6.3%
1Y
65.6%
Catalyst Pharmaceuticals
Market Cap: US$2.6b
A commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States.
CPRX
US$20.97
7D
-1.4%
1Y
-1.7%
Exelixis
Market Cap: US$9.7b
An oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.
EXEL
US$36.08
7D
-9.9%
1Y
27.4%
Waters
Market Cap: US$20.8b
Provides analytical workflow solutions in Asia, the Americas, and Europe.
WAT
US$348.67
7D
4.9%
1Y
4.6%
ACADIA Pharmaceuticals
Market Cap: US$3.6b
A biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United States.
ACAD
US$21.39
7D
-1.6%
1Y
49.7%
Harmony Biosciences Holdings
Market Cap: US$1.5b
A commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States.
HRMY
US$26.27
7D
-1.4%
1Y
-22.8%
Incyte
Market Cap: US$17.2b
A biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan.
INCY
US$88.06
7D
0.9%
1Y
35.0%
CytomX Therapeutics
Market Cap: US$596.2m
Operates as an oncology-focused biopharmaceutical company that focuses on developing novel conditionally activated biologics localized to the tumor microenvironment.
CTMX
US$3.39
7D
-0.6%
1Y
213.9%
Corcept Therapeutics
Market Cap: US$7.9b
Engages in discovery and development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States.
CORT
US$73.65
7D
-4.1%
1Y
53.2%
Niagen Bioscience
Market Cap: US$600.2m
Operates as a bioscience company engages in developing healthy aging products.
NAGE
US$7.43
7D
-0.9%
1Y
114.7%
ADMA Biologics
Market Cap: US$3.5b
A biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.
ADMA
US$15.16
7D
0.5%
1Y
-3.4%
Earth Science Tech
Market Cap: US$52.4m
Together with its subsidies, focuses on health and wellness industry.
ETST
US$0.18
7D
4.3%
1Y
28.6%
CureVac
Market Cap: US$1.2b
A biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA).
CVAC
US$5.39
7D
-0.2%
1Y
99.6%
Champions Oncology
Market Cap: US$91.6m
A technology-enabled research company, provides technology solutions for drug discovery and development in the United States.
CSBR
US$6.70
7D
1.8%
1Y
67.1%
BioStem Technologies
Market Cap: US$88.9m
A life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services.
BSEM
US$4.89
7D
1.3%
1Y
-65.0%
Puma Biotechnology
Market Cap: US$260.4m
A biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally.
PBYI
US$5.23
7D
-4.9%
1Y
86.1%